Back to Search
Start Over
Additional file 3: of A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease
- Publication Year :
- 2017
- Publisher :
- Figshare, 2017.
-
Abstract
- Change from baseline in maximum voluntary ventilation (MVV). Mean changes from baseline to week 72 in subjects receiving 20Â mg/kg reveglucosidase alfa infusion every 2Â weeks. Baseline is defined as the last measurement prior to the first infusion. The error bars represent the standard deviations. The statistical significance of treatment effects was not determined, as no pre-planned statistical analyses were conducted for this study. (PDF 122Â kb)
Details
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....72603febe2daeea6a04b89e60a40b9b8
- Full Text :
- https://doi.org/10.6084/m9.figshare.c.3863143_d3